Clinical Benefit of Sorafenib Combined with Paclitaxel and Carboplatin to a Patient with Metastatic Chemotherapy‐Refractory Testicular Tumors

Testicular cancer is one of the few tumor types that have not yet benefited from targeted therapy. Still no new active agents for treating this cancer have been identified over the past 15 years. Once patients are refractory to cisplatin‐based chemotherapy, they will be expected to die from testicul...

Descripción completa

Detalles Bibliográficos
Autores principales: Lian, Bijun, Zhang, Wenhui, Wang, Tiegong, Yang, Qingsong, Jia, Zepeng, Chen, Huan, Wang, Lei, Xu, Jing, Wang, Wei, Cao, Kai, Gao, Xu, Sun, Yinghao, Shao, Chengwei, Liu, Zhiyong, Li, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Precision Medicine Clinic: Molecular Tumor Board
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6975956/
https://www.ncbi.nlm.nih.gov/pubmed/31492770
http://dx.doi.org/10.1634/theoncologist.2019-0295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6975956/
https://www.ncbi.nlm.nih.gov/pubmed/31492770
http://dx.doi.org/10.1634/theoncologist.2019-0295

Ejemplares similares